Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBITDA (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of EBITDA data on record, last reported at $63.3 million in Q4 2025.

  • For Q4 2025, EBITDA rose 519.33% year-over-year to $63.3 million; the TTM value through Dec 2025 reached $44.7 million, up 3583.55%, while the annual FY2025 figure was $44.7 million, 3583.55% up from the prior year.
  • EBITDA reached $63.3 million in Q4 2025 per ORGO's latest filing, up from $20.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $63.3 million in Q4 2025 and bottomed at -$26.7 million in Q1 2025.
  • Average EBITDA over 5 years is $7.5 million, with a median of $8.4 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 1147.38% in 2021, then crashed 3025.78% in 2023.
  • A 5-year view of EBITDA shows it stood at $19.8 million in 2021, then plummeted by 55.86% to $8.7 million in 2022, then tumbled by 114.56% to -$1.3 million in 2023, then surged by 905.28% to $10.2 million in 2024, then soared by 519.33% to $63.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $63.3 million in Q4 2025, $20.7 million in Q3 2025, and -$12.6 million in Q2 2025.